The thesis

Alnylam develops RNA interference therapeutics, a technology now generating real commercial revenue. Revenue grew 66.9% year-over-year, a pace that supports the bull narrative on drug launches like Amvuttra and Onpattro. Yet the composite conviction score sits at just 34/100, and the DCF model spits out a negative intrinsic value of -$1613, a signal that cash-flow assumptions or terminal value inputs are breaking down. Reported gross margin of 7972% and net margin of 1682% are mathematically impossible for a normal operating business, pointing to one-time royalty or licensing accounting that inflates the picture and should not be read as durable profitability.

Why now

Analyst consensus remains BUY even as the quantitative composite conviction lands at HIGH tier but a low 34/100 score, a split that demands scrutiny before the next earnings print. Treasury sanctions rhetoric on Iran signals a broader risk-off macro backdrop, and the model's own risk-off rotation driver is marked inactive despite strong evidence, another inconsistency worth tracking as rates and risk appetite shift.

What to watch

Watch the next quarterly filing for normalized gross and net margins that strip out one-time licensing or royalty effects, since the current 7972% and 1682% figures cannot persist. Track whether the 66.9% revenue growth rate holds as recent drug launches mature, and whether analyst consensus shifts if the conviction composite score fails to move off 34/100.

Key risks

The negative DCF value of -$1613 suggests the market-implied growth assumptions may not be supportable long-term, a valuation risk that a 43.9x P/E does nothing to resolve. The extreme margin figures likely reflect non-recurring items, so any read-through to sustainable earnings power is unreliable until normalized financials are available. Macro risk from an escalating sanctions regime could pressure biotech risk appetite broadly, regardless of Alnylam's own execution.

Theme exposure